Quantbot Technologies LP Sells 7,499 Shares of Halozyme Therapeutics, Inc. $HALO

Quantbot Technologies LP lessened its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 47.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,373 shares of the biopharmaceutical company’s stock after selling 7,499 shares during the period. Quantbot Technologies LP’s holdings in Halozyme Therapeutics were worth $614,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Root Financial Partners LLC bought a new stake in Halozyme Therapeutics in the 3rd quarter valued at $25,000. Richardson Financial Services Inc. raised its stake in Halozyme Therapeutics by 87.6% during the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 198 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new stake in shares of Halozyme Therapeutics during the second quarter worth $32,000. Employees Retirement System of Texas bought a new stake in Halozyme Therapeutics during the 2nd quarter worth $34,000. Finally, Clearstead Advisors LLC increased its position in Halozyme Therapeutics by 107.7% in the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 265 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $70.21, for a total transaction of $702,100.00. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at $53,905,833.80. This represents a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the sale, the director owned 40,123 shares of the company’s stock, valued at $2,818,640.75. The trade was a 4.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 62,000 shares of company stock worth $4,545,200. Corporate insiders own 2.90% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $67.37 on Monday. The firm has a market cap of $7.95 billion, a PE ratio of 27.06, a price-to-earnings-growth ratio of 0.27 and a beta of 0.98. Halozyme Therapeutics, Inc. has a 12-month low of $47.50 and a 12-month high of $82.22. The company’s fifty day simple moving average is $72.66 and its two-hundred day simple moving average is $70.72. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of $1.92 by ($2.16). Halozyme Therapeutics had a net margin of 22.69% and a return on equity of 136.12%. The business had revenue of $451.77 million for the quarter, compared to the consensus estimate of $446.13 million. During the same quarter in the prior year, the company earned $1.26 EPS. Halozyme Therapeutics’s revenue was up 51.6% compared to the same quarter last year. As a group, equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analyst Upgrades and Downgrades

HALO has been the subject of several recent analyst reports. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, January 29th. Wells Fargo & Company upped their price objective on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 19th. Benchmark increased their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Finally, Weiss Ratings lowered shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Tuesday, February 24th. Six research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $78.56.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.